|
Abingdon Health PLC - London-based developer of rapid-flow diagnostic tests - Says saliva-based pregnancy test Salistick to be launched in various key European territories including Austria, Poland and Germany. Salistick is based on technology by Jerusalem-based saliva diagnostics firm Salignostics, with which Abingdon has extended its distribution agreement. Abingdon says it previously successfully launched Salistick in the UK, and that the agreement for the German market is on an exclusive basis. Abingdon and distribution partner NeutraPharma expect to launch own-brand Salistick with various ‘major German retailers’ in the second quarter of this calendar year. Says it has received an initial purchase order for 70,000 tests with further orders expected during 2025 on a quarterly basis. Abingdon Chief Executive Officer Chris Yates comments: ‘We are incredibly proud and excited to be launching Salistick, the first saliva pregnancy test, in Germany and other European territories following on from our successful commercial roll-out in the UK. This exciting innovation offers the opportunity to test for pregnancy anytime, anywhere. We are delighted to extend our partnerships with Salignostics and NeutraPharma and we look forward to continuing to work with them to bring further innovative self-test products to market.’ Current stock price: 6.96 pence, up 3.1% on Monday in London 12-month change: down 18% Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
